218 related articles for article (PubMed ID: 9044859)
1. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer.
Lokeshwar VB; Obek C; Soloway MS; Block NL
Cancer Res; 1997 Feb; 57(4):773-7. PubMed ID: 9044859
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.
Pham HT; Block NL; Lokeshwar VB
Cancer Res; 1997 Feb; 57(4):778-83. PubMed ID: 9044860
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
[TBL] [Abstract][Full Text] [Related]
4. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
5. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1.
Lokeshwar VB; Young MJ; Goudarzi G; Iida N; Yudin AI; Cherr GN; Selzer MG
Cancer Res; 1999 Sep; 59(17):4464-70. PubMed ID: 10485499
[TBL] [Abstract][Full Text] [Related]
6. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
7. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
[TBL] [Abstract][Full Text] [Related]
8. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
[TBL] [Abstract][Full Text] [Related]
9. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder.
Passerotti CC; Bonfim A; Martins JR; Dall'Oglio MF; Sampaio LO; Mendes A; Ortiz V; Srougi M; Dietrich CP; Nader HB
Eur Urol; 2006 Jan; 49(1):71-5. PubMed ID: 16310928
[TBL] [Abstract][Full Text] [Related]
10. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
11. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
[TBL] [Abstract][Full Text] [Related]
14. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma.
Wang XS; Zhang Z; Wang HC; Cai JL; Xu QW; Li MQ; Chen YC; Qian XP; Lu TJ; Yu LZ; Zhang Y; Xin DQ; Na YQ; Chen WF
Clin Cancer Res; 2006 Aug; 12(16):4851-8. PubMed ID: 16914571
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
16. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
18. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
19. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
[TBL] [Abstract][Full Text] [Related]
20. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]